(NP (NP (JJ Differential) (NN autoregulation)) (PP (IN of) (NP (NN glucocorticoid) (NN receptor) (NN expression))) (PP (IN in) (NP (JJ human) (NP-COOD (NP (NN T-) (NP (-NONE- *?*))) (CC and) (NP (NN B-cell))) (NNS lines))) (. .))
(S (NP-SBJ-14 (NP (NN Regulation)) (PP (IN of) (NP (NP (NP (NN glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (NN expression))) (PP (IN by) (NP (PRP$ its) (JJ cognate) (NN ligand)))) (VP (VBD was) (VP (VBN examined) (NP (-NONE- *-14)) (PP-COOD (PP (IN in) (NP (DT the) (JJ glucocorticoid-sensitive) (JJ human) (JJ leukemic) (NN T-cell) (NN line) (NN 6TG1.1))) (CC and) (PP (IN in) (NP (DT the) (JJ human) (NN B-cell) (NN line) (NN IM-9)))))) (. .))
(S (PP (IN In) (NN contrast) (TO to) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NN GR) (NN mRNA))) (VP (VBN seen) (NP (-NONE- *)) (PP (IN in) (NP (NN IM-9) (NNS cells))) (PP-TMP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (ADJP (CD 1) (NN microM)) (NN dexamethasone))) (PP-TMP (IN for) (NP (QP (CD 16-18)) (NN h)))))))) (, ,) (NP-SBJ (NP (NN treatment)) (PP (IN of) (NP (NN 6TG1.1) (NNS cells)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ 8-fold) (NN increase)) (PP (IN in) (NP (NN GR) (NN mRNA))))) (, ,) (SBAR (IN as) (S (NP-SBJ-15 (-NONE- *)) (VP (VBN determined) (NP (-NONE- *-15)) (PP (IN by) (NP (NP-COOD (NP (NN Northern) (NN blot)) (CC and) (NP (NN RNase) (NN protection))) (NN analysis)))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ corresponding) (ADJP-COOD (ADJP (NP (CD 3-)) (ADJP (-NONE- *?*))) (TO to) (ADJP (JJ 4-fold))) (NN increase)) (PP (IN in) (NP (NN GR) (NN protein)))))) (. .))
(S-COOD (S (NP-SBJ-16 (NP (JJ Half-maximal) (NN induction)) (PP (IN of) (NP (NN GR) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein))))) (PP (IN in) (NP (NN 6TG1.1) (NNS cells)))) (VP (VBD was) (VP (VBN observed) (NP (-NONE- *-16)) (PP (IN between) (NP (ADJP (QP (CD 10-100)) (NN nM)) (NN dexamethasone)))))) (, ,) (CC and) (S (NP-SBJ (NP (NN inclusion)) (PP (IN of) (NP (ADJP (CD 1) (NN microM)) (NN RU) (CD 38486)))) (ADVP (RB completely)) (VP (VBD blocked) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (ADJP (CD 100) (NN nM)) (NN dexamethasone)))) (, ,) (S (NP-SBJ (-NONE- *)) (VP (VBG demonstrating) (SBAR (IN that) (S (NP-SBJ (NP (JJ positive) (NN autoregulation)) (PP (IN of) (NP (NN GR) (NN expression))) (PP (IN in) (NP (NN 6TG1.1) (NNS cells)))) (VP (VBZ is) (NP-PRD (DT a) (JJ receptor-mediated) (NN response))))))))) (. .))
(S (NP-SBJ-17 (NP (JJ Positive) (NN autoregulation)) (PP (IN of) (NP (NN GR) (NN expression)))) (VP (VBD was) (VP (ADVP (RB also)) (VBN observed) (NP (-NONE- *-17)) (PP (IN in) (NP (NP (JJ glucocorticoid-resistant) (NN CEM-C1) (NNS cells)) (, ,) (SBAR-COOD (SBAR (WHNP-18 (WDT which)) (S (NP-SBJ (-NONE- *T*-18)) (VP (VBP contain) (NP (JJ functional) (NN GR))))) (, ,) (CC but) (SBAR (WHNP-20 (WP$ whose) (NN growth)) (S (NP-SBJ-19 (-NONE- *T*-20)) (VP (VBZ is) (VP (VBN unaffected) (NP (-NONE- *-19)) (PP (IN by) (NP-LGS (NNS glucocorticoids)))))))))))) (. .))
(S (ADVP (RB Thus)) (, ,) (NP-SBJ (JJ positive) (NN autoregulation)) (VP (VBZ is) (NP-PRD (NP-COOD (CC neither) (NP (DT a) (NN consequence)) (CC nor) (NP (DT the) (JJ sole) (NN cause))) (PP (IN of) (NP (NN growth) (NN arrest))))) (. .))
(S (NP-SBJ-21 (NP (DT The) (NN degree)) (PP (IN of) (NP-COOD (NP (NP (JJ negative) (NN autoregulation)) (PP (IN in) (NP (NN IM-9) (NNS cells)))) (CC and) (NP (NP (JJ positive) (NN autoregulation)) (PP (IN in) (NP (NN 6TG1.1) (NNS cells))))))) (VP (VBD was) (VP (VBN unaffected) (NP (-NONE- *-21)) (PP (IN by) (NP-LGS (NP (NN inhibition)) (PP (IN of) (NP (NP (NN protein) (NN synthesis)) (PP (IN with) (NP (NN cycloheximide))))))))) (. .))
(S (NP-SBJ (NP (NN Measurement)) (PP (IN of) (NP (NP (NN GR) (NN mRNA) (NN turnover)) (PP (IN in) (NP (NP (NN 6TG1.1) (NNS cells)) (VP (VBN treated) (NP (-NONE- *)) (PP (IN with) (NP (NN actinomycin-D))))))))) (VP (VBD revealed) (NP (NP (DT a) (NN half-life)) (PP (IN of) (NP (CD 2.5) (NN h))) (, ,) (SBAR (WHNP-22 (WDT which)) (S (NP-SBJ-23 (-NONE- *T*-22)) (VP (VBD was) (VP (JJ unaffected) (NP (-NONE- *-23)) (PP (IN by) (NP-LGS (NN dexamethasone) (NN treatment))))))))) (. .))
(S (NP-SBJ-24 (DT A) (JJ similar) (NN half-life)) (VP-COOD (VP (VBD was) (VP (VBN determined) (NP (-NONE- *-24)) (PP (IN in) (NP (NN IM-9) (NNS cells))))) (CC and) (VP (VBD was) (ADVP (RB also)) (VP (JJ unaffected) (NP (-NONE- *-24)) (PP (IN by) (NP-LGS (NN steroid) (NN treatment)))))) (. .))
(S (NP-SBJ (DT These) (NNS results)) (VP (VBP are) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (DT the) (NN interpretation) (SBAR (IN that) (S (NP-SBJ (NP (JJ glucocorticoid-mediated) (NN autoregulation)) (PP (IN of) (NP (NN GR) (NN expression)))) (VP (VBZ is) (NP-PRD (DT a) (JJ tissue-specific) (JJ primary) (JJ transcriptional) (NN response))))))))) (. .))
